Endocrine aspects of benign breast disease.
The purpose of this study was to determine the levels of dehydroepiandrosterone sulfate (DHAS) in the plasma of women with benign breast disease (BBD) and in normal subjects. Possible changes in DHAS plasma levels and in its adrenal secretion under adrenocorticotrophin hormone (ACTH) were also investigated in women with BBD before and after bromocriptine therapy. Our results demonstrate that plasma levels of DHAS in women with BBD overlap with those found in controls. Prolactin (PRL) suppression in women with BBD receiving bromocriptine treatment was associated with a significant (p less than 0.02) decrease of baseline DHAS plasma levels and of stimulated ACTH response curve (p less than 0.02). These data suggest a possible relationship between PRL and DHAS secretion in women with BBD.
Parlati
E
E
Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
Liberale
I
I
Travaglini
A
A
Morelli
P
P
Menini
E
E
Dell'Acqua
S
S
D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000328:Adult; D000728:Androgens / Q000378:metabolism; D001941:Breast Diseases / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D001971:Bromocriptine / Q000627:therapeutic use; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives* / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate; D004702:Endocrine Glands / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D013268:Stimulation, Chemical
D000728:Androgens; D001971:Bromocriptine; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate; D000324:Adrenocorticotropic Hormone; D011388:Prolactin